SEC Form 4 · accession 0000899243-17-018293
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
David L Mahoney
Director
Period of report
Jul 12, 2017
Accepted (ET)
Jul 14, 2017 · 5:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 12, 2017 | S | 6,510 | $12.50 | D | 1,129,163 | I | Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust |
| Common StockF2 | Jul 13, 2017 | S | 484 | $12.548 | D | 1,128,679 | I | Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale is made pursuant to terms of 10b5-1 plan in effect at the time of sale of the shares.
- F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $12.52 to $12.56 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.